Kiniksa Pharmaceuticals Ltd Asset Resilience Ratio
Kiniksa Pharmaceuticals Ltd asset resilience ratio. Kiniksa Pharmaceuticals Ltd (KNSA) has an Asset Resilience Ratio of 39.09% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KNSA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Kiniksa Pharmaceuticals Ltd (2016–2025)
Asset resilience ratio of Kiniksa Pharmaceuticals Ltd from 2016 to 2025. This chart shows how Kiniksa Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Kiniksa Pharmaceuticals Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Kiniksa Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see KNSA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $350.25 Million | 39.09% |
| Total Liquid Assets | $350.25 Million | 39.09% |
Asset Resilience Insights
- Very High Liquidity: Kiniksa Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 39.09% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kiniksa Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Kiniksa Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Kiniksa Pharmaceuticals Ltd Asset Resilience Ratio by Year (2016–2025)
Kiniksa Pharmaceuticals Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Kiniksa Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 32.54% | $248.48 Million | $763.63 Million | +22.20pp |
| 2024-12-31 | 10.34% | $60.05 Million | $580.55 Million | -8.36pp |
| 2023-12-31 | 18.70% | $98.42 Million | $526.32 Million | +3.93pp |
| 2022-12-31 | 14.77% | $67.89 Million | $459.67 Million | -10.89pp |
| 2021-12-31 | 25.66% | $59.73 Million | $232.80 Million | -34.28pp |
| 2020-12-31 | 59.93% | $209.44 Million | $349.46 Million | -13.32pp |
| 2019-12-31 | 73.25% | $186.45 Million | $254.53 Million | +0.16pp |
| 2018-12-31 | 73.09% | $235.33 Million | $321.96 Million | +72.87pp |
| 2017-12-31 | 0.22% | $105.00K | $47.49 Million | +0.04pp |
| 2016-12-31 | 0.19% | $105.00K | $56.47 Million | -- |
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more